Lv1
16 积分 2024-03-26 加入
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
6小时前
待确认
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
8小时前
已完结
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
10小时前
已完结
Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer
10天前
已完结
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
23天前
已完结
Identification of novel gene expression patterns and pathways involved in PARP-1 inhibitor resistance
1个月前
已完结
Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors
2个月前
已完结
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
2个月前
已完结
Synergistic Effects of Olaparib and Palbociclib in Resistant epithelial ovarian cancer
3个月前
已完结
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
3个月前
已完结
皖公网安备34019202002308
